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Abstract
The kynurenine pathway (KP) of tryptophan (TRP) catabolism links immune system activation with neurotransmitter
signaling. The KP metabolite kynurenic acid (KYNA) is increased in the brains of people with schizophrenia. We tested the
extent to which: (1) brain KP enzyme mRNAs, (2) brain KP metabolites, and (3) plasma KP metabolites differed on the basis
of elevated cytokines in schizophrenia vs. control groups and the extent to which plasma KP metabolites were associated
with cognition and brain volume in patients displaying elevated peripheral cytokines. KP enzyme mRNAs and metabolites
were assayed in two independent postmortem brain samples from a total of 71 patients with schizophrenia and 72 controls.
Plasma KP metabolites, cognition, and brain volumes were measured in an independent cohort of 96 patients with
schizophrenia and 81 healthy controls. Groups were stratiﬁed based on elevated vs. normal proinﬂammatory cytokine
mRNA levels. In the prefrontal cortex (PFC), kynurenine (KYN)/TRP ratio, KYNA levels, and mRNA for enzymes,
tryptophan dioxygenase (TDO) and kynurenine aminotransferases (KATI/II), were signiﬁcantly increased in the high
cytokine schizophrenia subgroup. KAT mRNAs signiﬁcantly correlated with mRNA for glial ﬁbrillary acidic protein in
patients. In plasma, the high cytokine schizophrenia subgroup displayed an elevated KYN/TRP ratio, which correlated
inversely with attention and dorsolateral prefrontal cortex (DLPFC) volume. This study provides further evidence for the role
of inﬂammation in a subgroup of patients with schizophrenia and suggests a molecular mechanism through which
inﬂammation could lead to schizophrenia. Proinﬂammatory cytokines may elicit conversion of TRP to KYN in the periphery
and increase the N-methyl-D-aspartate receptor antagonist KYNA via increased KAT mRNA and possibly more enzyme
synthesis activity in brain astrocytes, leading to DLPFC volume loss, and attention impairment in schizophrenia.
Introduction
In addition to disturbances in neurotransmitter systems,
recent genetic [1], molecular neuropathology [2], and
clinical studies [3] have highlighted the importance of
immunological factors in the pathogenesis and treatment of
schizophrenia. Low-grade inﬂammation is found in both
postmortem brain tissue [2, 4] and in plasma of approxi-
mately 40% of people with schizophrenia (termed a “high-
cytokine biotype”) [5]. While considerable evidence sug-
gests a role for inﬂammation in the pathophysiology of
schizophrenia, the mechanism by which neuroinﬂamma-
tion inﬂuences neurotransmitter systems is unknown.
However, neuroactive degradation products of tryptophan
(TRP) are produced via the kynurenine pathway (KP),
which is regulated by the immune system. The breakdown
of TRP via the KP is activated by proinﬂammatory cyto-
kines [6–8] inducing a catabolic cascade that produces
metabolites that can either block or activate neuro-
transmitter receptors in the brain [9]. Therefore, the KP is
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considered to link the immune and neurotransmitter
systems.
While TRP is commonly thought of as a precursor of the
neurotransmitter serotonin, TRP can also be degraded to
kynurenine (KYN) [10, 11]. KYN is catabolized to either
kynurenic acid (KYNA) via kynurenine aminotransferases
(KATs [12], mostly located in brain astrocytes) or to 3-
hydroxykynurenine (3-HK) via kynurenine 3-
monooxygenase (KMO [13], mostly located in brain
microglia) and eventually to quinolinic acid (QUINA).
KATI and KATII are the biosynthetic enzymes of KYNA in
the mammalian brain [6]. For an overview of the KP, see
Fig. 1. Proinﬂammatory cytokines, e.g., interleukin (IL)-1β,
interferon-γ, and IL-6, stimulate an important pathway in
macrophages featuring indoleamine 2,3 dioxygenase (IDO)
[6, 7], the rate-limiting enzyme degrading TRP into KYN,
and KYN can cross the blood–brain barrier (BBB). KYNA,
3-HK, and QUINA possess neuroactive properties and are
known to modulate dopaminergic, nicotinergic, and gluta-
matergic neurotransmission [14–16]. Whereas QUINA is an
N-methyl-D-aspartate receptor (NMDAR) agonist that can
cause excitotoxic neurodegeneration and 3-HK can cause
neuronal apoptosis, KYNA is an NMDAR antagonist that is
considered to protect against excitotoxic and apoptotic
effects [9, 17]. However, in schizophrenia, increased
KYNA in the brain may lead to excessive NMDAR
blockade, which is a known trigger of psychotic symptoms
and cognitive deﬁcits (e.g., with NMDAR antagonists
phencyclidine and ketamine) [18].
Increased concentrations of KYN and KYNA have been
found in postmortem prefrontal cortex (PFC) brain tissue
[19, 20] and cerebrospinal ﬂuid (CSF) [21–23] of people
with schizophrenia. Moreover, genetic variants in KP
enzymes have been linked to psychotic symptoms,
cognitive dysfunction, and abnormal levels of KYNA in
schizophrenia [20] and bipolar disorder [24]. This has led to
the formulation of the KYNA hypothesis of schizophrenia,
centering on the idea that increased KYNA levels cause
positive symptoms and cognitive deﬁcits via NMDAR
blockade [25]. This is supported by recent studies demon-
strating that stress-induced salivary KYNA response in
schizophrenia was inversely associated with glutamate
levels in schizophrenia [26, 27]. Also, increased intracer-
ebral KYNA in schizophrenia is related to decreased KMO
enzyme activity in microglia [20]. However, reduced KMO
activity is only indirect evidence of increased KYNA pro-
duction and KYNA may be expected to be directly related
to increased KAT activity since KYNA is produced by
KATI/II enzyme activity. Human astrocytes express KATI/
II, converting KYN to KYNA, but do not express KMO.
Hence, astrocytes are probably the largest producer of
KYNA in the brain [28].
Importantly, brain KYNs are linked to and inﬂuenced
by the peripheral KP [9, 27]. One study indicated that
Toxoplasma gondii infections enhance production of brain
KP metabolites in mice [29], thereby emphasizing the
effect of peripheral infections on KYNA levels in the
brain. Metabolism in the pathway is driven by blood-
derived TRP, KYN, and 3-HK that cross the BBB,
whereas KYNA and QUINA cannot cross the BBB due to
their polar nature [9]. The breakdown of TRP to KYN
reﬂects the level of activity within the KP; and higher
KYN/TRP plasma ratios have been consistently reported
in schizophrenia [30–32]. There is a positive association
between the proinﬂammatory cytokine IL-6 and both the
KYN/TRP and KYNA/TRP ratios in CSF of patients with
schizophrenia [22], and this ﬁnding highlights the inter-
action between activation of inﬂammation and the KYN/
TRP ratio. Furthermore, one recent study showed that
increased plasma KYN/TRP levels in schizophrenia were
inversely correlated with frontal white matter glutamate
levels [30], providing the ﬁrst evidence that plasma KYN
levels can be used as a peripheral indicator of brain
changes related to deleterious alterations in cortical neu-
rotransmission. Thus there is evidence supporting the
hypothesis that KP metabolites can be used as peripheral
markers of brain dysfunction in schizophrenia.
Therefore, we examined postmortem PFC brain tissue
from two independent samples of patients and controls
and measured brain KP metabolites. We also measured
peripheral plasma KP metabolites, cognition, and brain
volume in an independent large sample of patients with
schizophrenia and healthy controls. Since cytokines can
activate the KP, we predicted that increased KP enzyme
mRNA should be evident in high cytokine subgroups of
schizophrenia. Speciﬁcally, we expected to ﬁnd mRNA
levels of TDO and KATI/II mRNAs to be increased in
Fig. 1 Overview of the kynurenine pathway (KP). TDO tryptophan-
2,3-dioxygenase, IDO indoleamine 2,3 dioxygenase, IL-1β interleukin
1 beta, IL-6 interleukin 6, KMO kynurenine 3 monooxygenase, KAT
kynurenine amino transferase, GFAP glial ﬁbrillary acidic protein,
IBA ionized calcium-binding adaptor molecule, KYNU kynureninase,
3HAO 3-hydroxyanthranilic acid 3,4-dioxygenase
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schizophrenia and KMO mRNA to be decreased in schi-
zophrenia, particularly among those patients in the high
cytokine subgroup. In addition, we expected to ﬁnd a
higher KYN/TRP ratio, higher KYNA levels, and a higher
KYNA/QUINA ratio in postmortem tissue of patients in
the high cytokine subgroup. In the cohort of living people,
we predicted an increased KYN/TRP ratio in the plasma
of patients with schizophrenia compared to controls and
that the increased ratio would be more pronounced in the
high cytokine subgroup of patients. In addition, we
expected that the plasma KYN/TRP ratio would be
inversely correlated with executive functioning (working
memory and attention) and PFC volume of chronically ill
patients with schizophrenia who display increased proin-
ﬂammatory cytokines.
Materials and methods
Postmortem cohorts
Tissue Resource Center (TRC) cohort
Postmortem brain tissue samples in this cohort were
obtained from the New South Wales TRC. Tissue from the
dorsal lateral prefrontal cortex (DLPFC) i.e., middle frontal
gyrus, was obtained for 37 individuals with schizophrenia
and 37 controls (40 subjects from the right and in 34 from
the left hemisphere). Fresh frozen tissue was pulverized and
total RNA was extracted using Trizol and complementary
DNA (cDNA) was synthesized using Superscript III, as
described in Weickert et al. [33]. The present study was
performed in accordance with the latest version of the
Declaration of Helsinki after review by the Human
Research Ethics Committee at the University of New South
Wales (UNSW), (HREC #12435).
Stanley Medical Research Institute (SMRI) cohort
This cohort includes brain tissue of the middle frontal gyrus
from 34 schizophrenia patients and 35 controls received
from SMRI. Total RNA from postmortem brain tissue
samples were obtained from the SMRI. Tissue character-
istics, total RNA extraction, and cDNA synthesis details are
provided elsewhere [4]. The present study was performed in
accordance with the latest version of the SMRI ethics
(http://www.SMRIresearch.org/brain-research/).
Quantitative real-time PCR (qPCR)—postmortem cohort
The normalized mRNA expression of KAT I, KAT II,
TDO, and KMO, IL-1β, IL-6, IL-8 and Serpin Family A
Member 3 (SERPINA3) in the human DLPFC was
measured by reverse transcriptase–qPCR (7900HT, Applied
Biosystems, Foster City, CA, USA) using pre-designed
Taqman Gene Expression Assays in both cohorts. The
transcripts for glial ﬁbrillary acidic protein (GFAP) and
ionized calcium-binding adapter molecule 1 (IBA1) were
also measured in the TRC cohort. For quantitation via
qPCR, we used four mRNAs including ACTB
(Hs99999903_m1), GAPDH (Hs99999905_m1), TBP
(Hs00427621_m1), and UBC (Hs00824723_m1) as nor-
malizing genes. For more details, see Supplemental Meth-
ods: Quantitative real-time PCR postmortem cohort.
KYN metabolite assays—postmortem cohort
KP pathway metabolites (TRP, KYN, KYNA, QUINA)
were assayed from brain tissue, PFC, of the TRC cohort
(total n= 74) using ultra-high-performance liquid chroma-
tography and gas chromatography–mass spectrometry.
Results were normalized to brain tissue mass. For details,
see Supplemental Methods: Kynurenine Pathway Metabo-
lite assays – Postmortem cohort.
Living cohort
Participants
Ninety-six chronically ill patients meeting the Diagnostic
and Statistical Manual of Mental Disorders, Fourth edition
(DSM-IV) criteria for schizophrenia or schizoaffective dis-
order on the basis of the Structured Clinical Interview for
DSM-IV Axis 1 disorders [34] and 81 healthy adults were
recruited from two sites (Adelaide and Sydney). For details,
see Supplemental Methods: Participants – Living cohort.
All procedures were approved by the UNSW (07–121,
09–187) and South-Eastern Sydney and Illawarra Area
Health Service (07–259) Human Research Ethic Commit-
tees, Sydney and the Queen Elizabeth Hospital (2010188)
Ethics and Human Research Committee, Adelaide. Written
informed consent was obtained from each participant before
entry into the study.
KYN metabolite assays—living cohort
Blood plasma samples were collected from each participant
between 8 and 11 a.m. on the day of the magnetic resonance
imaging (MRI) scan and cognitive assessments. Assays of
TRP, KYN, KYNA, 3-HK, and QUINA were performed as
described previously [35]. In addition, C-reactive protein
(CRP) was measured in plasma of the living cohort, which
is a good indicator for central inﬂammation [36]. For
details, see Supplemental Methods: Kynurenine Pathway
Metabolite assays – Living cohort, CRP assays – Living
cohort.
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Cognitive assessments—living cohort
Cognitive domains of verbal memory, language, working
memory, processing speed, and perceptual organization
were formed as described previously [37]. For details, see
Supplemental Methods: Cognitive testing and cognitive
domain formation – Living cohort.
Gray matter volume data collection and processing—living
cohort
MRI was performed on a subset from the whole living
sample consisting of 62 patients and 62 controls using a 3-T
Phillips Achieva MRI scanner at Neuroscience Research
Australia, Randwick, Australia. DLPFC was chosen as
the region of interest as prior studies have shown that
PFC volume is commonly abnormal in schizophrenia
[20, 38–41]. DLPFC was also selected to correspond to
regions sampled in the postmortem cohort tissue that
included the rostral middle frontal gyrus, bilaterally. For
details, see Supplemental Methods: Gray Matter volume
data collection and processing—living cohort.
Cytokine subgrouping
Given that the aim of this work was to determine whether
altered KP metabolites existed in subgroups of people with
schizophrenia who were classiﬁed on the basis of elevated/
normal peripheral cytokine levels, our primary analyses
were based on our previously established elevated and
normal cytokine subgroups [2, 4, 5, 42].
Cytokine subgrouping—postmortem cohorts
The low/high cytokine subgroups in the postmortem cohort
controls and schizophrenia patients have been described in
more detail previously [2, 4]. Preparation of cDNA and
qPCR experiments were performed as described previously
[2, 4, 42]. From brain tissue cDNA, we assayed for the
mRNA levels of: SERPINA3 (Hs003153674_m1), IL-6
(Hs00174131_m1), IL-6ST (Hs01006741_m1), IL-8
(HS00174103_m1), IL-1β (Hs01555410_m1), NFKB1
(Hs00765730_m1), and PTGS2 (Hs00153133_m1)
(Applied Biosystems, Foster City, CA, USA)]. These tar-
gets were chosen as being most indicative of neuroin-
ﬂammation in people with schizophrenia from a larger RNA
sequencing database. To identify inﬂammatory subgroups
based on cytokine mRNA expression, a recursive two-step
cluster analysis was performed on postmortem cohorts
initially using all 7 transcripts as input variables as pre-
viously described [2, 4]. Four inﬂammatory markers
(SERPINA3, IL-6, IL-1β, IL-8 mRNAs) predicted inﬂam-
matory cluster membership with a high degree of
conﬁdence, and thus the expression levels of all 4 mRNAs
were used to deﬁne the high cytokine subgroups as gener-
ated by the computer algorithm.
Cytokine subgrouping—living cohort
Transcript levels were measured by qPCR using Applied
Biosystems’ 7900HT Real-time PCR system (Foster City, CA,
USA). Pre-designed Taqman Gene Expression
Assays: Interleukin-1β (Hs01555410_m1), Interleukin-6
(Hs00174131_m1), Interleukin-8 (HS00174103_m1), and
Interleukin-18 (Hs01038788_m1) (Applied Biosystems, Foster
City, CA, USA) were used to quantify the expression of the
cytokine genes in the periphery. Three housekeeper genes:
Peptidylprolyl isomerase A (Hs99999904_m1), TATA box
binding protein (Hs00427620_m1), and ubiquitin C
(Hs00824723_m1), were used for normalization of the data. A
two-step cluster analysis was performed on all samples in the
cohort combined. In the living cohort, four proinﬂammatory
cytokines were measured based on the overlap with the
informative cytokines from the brain. We found that four
cytokine mRNAs (IL-18, IL-1β, IL-6, IL-8 in order of con-
tribution) signiﬁcantly contributed to the clustering model
(≥0.33 on a scale from 0.1 to 1.0) [42]. Based on these results,
patients and controls of both cohorts were separated into high
and low cytokine subgroups. For furthers details, see Supple-
mental Methods: Cytokine subgrouping-living cohort.
Analyses
Statistical analyses: postmortem cohort
All analyses were performed using SPSS (version 25, IBM,
Armonk, NY, USA). See Supplemental Table S1 for an
overview of the assumptions met in association with the
statistical tests related to the groups and metabolites ana-
lyzed. Group outliers were identiﬁed by Grubb’s test and
excluded. Owing to low sample size in the TRC (n= 4) and
SMRI (n= 9) control high cytokine subgroups, these
groups were not included in the postmortem cytokine
inﬂammation stratiﬁed subgroup analyses. However, the
results for these subgroups are included in Supplemental
Figure S1 provided for reference purposes. SMRI cohort KP
enzyme expression levels were normalized to the TRC
cohort healthy control low cytokine subgroup means to
combine the two cohorts. Diagnostic differences of KP
enzyme mRNA expression between schizophrenia patients
and controls in postmortem brain tissue cohorts were ana-
lyzed separately and combined. To determine differences
among cytokine subgroups, analyses of covariance
(ANCOVAs) were performed with KP enzyme mRNA
expression and KP metabolite levels and ratios as dependent
variables and inﬂammatory subgroups (those patients with
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schizophrenia who had high proinﬂammatory cytokines,
normal proinﬂammatory cytokines and healthy controls
with normal proinﬂammatory cytokine levels) as the
grouping variables, with age, RNA integrity number (RIN),
or postmortem interval (PMI) as a covariate as appropriate
and follow-up post hoc least signiﬁcant difference (LSD)
tests for signiﬁcant overall ANCOVA results. As an altered
inﬂammation/KP would lead to altered pH values, pH was
not used as a covariate. We preformed correlations of KAT
I, KAT II, and KMO mRNAs with GFAP and IBA1
mRNAs in the TRC cohort using Spearman correlations.
In the TRC cohort, differences in KP metabolite levels/
ratios (KYN/TRP ratio, KYNA, KYNA/QUINA ratio)
among cytokine subgroups were analyzed by analyses of
variance (ANOVAs)/ANCOVAs with KP metabolites as
the dependent variable and inﬂammatory subgroups
as grouping variables with age and PMI as covariates as
appropriate and follow-up post hoc LSD tests for signiﬁcant
overall ANOVA/ANCOVA results. All statistical tests were
considered signiﬁcant at p < 0.05, 2-tailed, and are reported
both as uncorrected and false discovery rate (FDR) cor-
rected. For more details, see Supplemental Methods: Sta-
tistical Analyses-postmortem cohort.
Statistical analyses: living cohort
Differences in KP metabolites between healthy controls and
people with schizophrenia were tested using a series of six
univariate ANCOVAs with diagnosis as ﬁxed factor, age as
a covariate, and with the ﬁve KP metabolites (TRP, KYN, 3-
HK, KYNA, QUINA) and the KYN/TRP ratio as dependent
variables. To determine the relationship of KP metabolites to
cognitive performance and brain volumes, we focused solely
on the KYN/TRP ratio given: (a) proinﬂammatory cytokines
directly inﬂuence the KYN/TRP ratio by driving the meta-
bolism of TRP to KYN via activation of IDO/TDO [9], (b)
previously reported ﬁndings of an increased KYN/TRP ratio
in schizophrenia [31, 32], and (c) the relationship of the
KYN/TRP ratio to brain glutamate levels in schizophrenia
[30]. Differences of the KYN/TRP ratio among people with
schizophrenia and healthy controls (separated for low and
high cytokine subgroups) were tested using an ANCOVA
with diagnosis and inﬂammation status (controls in the low
and high cytokine subgroups and people with schizophrenia
in the low and high cytokine subgroups) as grouping factors
and age as a covariate as appropriate, with follow-up post
hoc LSD tests for signiﬁcant overall ANCOVA results.
Pearson correlations of the brain volume region of interest
(rostral middle frontal gyrus) and the KYN/TRP ratio were
performed in each group (low and high cytokine healthy
control subgroups, low and high cytokine schizophrenia
subgroups separately). As the DLPFC is involved in atten-
tion and working memory, we also performed Pearson
correlations between tests of these two cognitive domains
and the KYN/TRP ratio in healthy controls and in both the
low cytokine and high cytokine schizophrenia subgroups
separately. Statistics were performed using SPSS 23.0. All
statistical tests were considered signiﬁcant at p < 0.05, 2-
tailed. Results are reported as uncorrected and FDR cor-
rected. For more details, see Supplemental Methods: Sta-
tistical Analyses – Living cohort.
Results
Postmortem cohort
We provide cohort demographics for our postmortem brains
on factors including gender, age, tissue pH, RINs, and PMIs
(Supplemental Results and Tables S2a and S2b). We
detected a few signiﬁcant correlations of KP metabolites
and mRNA expression with demographic variables
(Table S3) and with other potentially confounding factors
(e.g., medication) (Table S3c). We report group compar-
isons on the basis of sex (Table S4) and smoking history
(Table S5).
Increased TDO, KAT I, and KAT II mRNA levels in the
PFC of a high cytokine schizophrenia subgroup
As both postmortem cohorts showed increased KAT mRNA
in high cytokine schizophrenia (Supplemental Figure S1),
the cohorts were combined for further analyses to increase
power. In the PFC, we found signiﬁcant differences in brain
TDO mRNA among cytokine subgroups (F(2,120)= 4.04,
p= 0.02, FDR p= 0.03). Follow-up, post hoc LSD tests
showed that TDO expression was signiﬁcantly increased by
14% (p= 0.05) in the low cytokine schizophrenia subgroup
relative to normal cytokine controls and increased by 26%
(p= 0.01) in the high cytokine schizophrenia subgroup
relative to normal cytokine controls (see Fig. 2a). Similarly,
we found signiﬁcant differences in KAT I mRNA among
cytokine subgroups (F(2,122)= 6.83, p < 0.01, FDR p=
0.02). Follow-up, post hoc LSD tests showed that KAT I
mRNA levels were signiﬁcantly increased by 16% (p <
0.01) in the high cytokine schizophrenia subgroup relative
to the low cytokine schizophrenia subgroup and increased
by 19% (p < 0.0001) in the high cytokine schizophrenia
subgroup relative to normal cytokine controls (see Fig. 2b).
We also found signiﬁcant differences in KAT II mRNA
among cytokine subgroups (F(2,124)= 5.82, p < 0.01, FDR
p= 0.02). Follow-up, post hoc LSD tests showed that KAT
II mRNA was signiﬁcantly increased by 19% (p < 0.01) in
the high cytokine schizophrenia subgroup relative to the
low cytokine schizophrenia subgroup and increased by 15%
(p < 0.01) in the high cytokine schizophrenia subgroup
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relative to normal cytokine controls (see Fig. 2c). There
were no signiﬁcant differences among cytokine subgroups
in relation to KMO mRNAs (see Fig. 2d). Additional
information on enzyme mRNA levels on the basis of
diagnostic groups (Supplemental Figure S2) or diagnostic
inﬂammation subgroup in NSW TRC and SMRI cohorts
separately can be found in Supplemental Results (Supple-
mental Figure S1).
GFAP and IL-6 mRNAs correlate with mRNAs
encoding KAT I and II enzymes in the PFC of
schizophrenia patients
A moderately strong, signiﬁcant, positive correlation was
found between an astrocyte maker (GFAP) and KAT I
mRNAs in both healthy controls (ρ= 0.57, n= 33, p=
0.001, FDR p= 0.004, see Fig. 3a) and in patients with
schizophrenia (ρ= 0.45, n= 36, p < 0.01, FDR p= 0.02,
see Fig. 3b). A similar but slightly weaker correlation was
found between GFAP and KAT II mRNAs in patients with
schizophrenia (ρ= 0.37, n= 36, p= 0.03, FDR p= 0.04,
see Fig. 3d); however, there was no signiﬁcant correlation
between GFAP and KATII mRNAs in controls (ρ= 0.21,
n= 34, p= 0.25, FDR p= 0.25, see Fig. 3c). No signiﬁcant
correlations were found between a microglial marker
(IBA1) and KMO mRNAs in either patients with schizo-
phrenia or healthy controls.
In the TRC cohort, there were moderately strong, posi-
tive, signiﬁcant correlations between KAT I/II mRNAs and
many cytokines assessed (IL-1β, IL-6, and IL-8) and
SERPINA3 in schizophrenia and control groups (Supple-
mental Table S6). In contrast, we detected moderately
strong, signiﬁcant inverse correlations of KMO mRNA
levels to IL-1β and SERPINA3 mRNA levels (see Sup-
plemental Table S6) within the PFC of people with schi-
zophrenia. TDO mRNA did not show any signiﬁcant
correlations with any of the cytokine mRNAs assayed.
There were also moderately strong, signiﬁcant correlations
of KATI mRNA with IL-6 and SERPINA3 mRNAs in
people with schizophrenia in the SMRI cohort (Supple-
mental Table S6b).
Increased KYN/TRP ratio and increased KYNA in the
PFC of a high cytokine schizophrenia subgroup
In the PFC, we found signiﬁcant differences in the KYN/
TRP ratio among cytokine subgroups (F(2,66)= 8.25,
p= 0.001, FDR p= 0.003). Follow-up, post hoc LSD tests
Fig. 2 Inﬂammatory subgroup
differences of kynurenine
pathway enzyme mRNA
expression in New South Wales
Tissue Resource Centre (NSW
TRC) and Stanley Medical
Research Institute (SMRI)
combined postmortem brain
tissue. a Tryptophan-2,3-
dioxygenase (TDO) mRNA
expression was signiﬁcantly
greater in people with
schizophrenia who were in
the high cytokine subgroup
(p= 0.02). b Kynurenine
aminotransferase (KAT) I
mRNA expression was
signiﬁcantly greater in people
with schizophrenia who were
in the high cytokine subgroup
(p= 0.01) than other groups.
c Similarly, KAT II mRNA
expression was signiﬁcantly
greater in people with
schizophrenia who were in the
high cytokine subgroup (p=
0.01) than other groups. d No
statistically signiﬁcant
differences in kynurenine 3
monooxygenase (KMO) mRNA
expression were detected among
groups. *p < 0.05, **p < 0.01,
***p < 0.001
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showed that the KYN/TRP ratio was signiﬁcantly higher in
the high cytokine schizophrenia subgroup relative to normal
cytokine schizophrenia subgroup of patients (p < 0.001) and
relative to normal controls (p < 0.001, Fig. 4a).
Further, we found signiﬁcant differences in KYNA
among cytokine subgroups (F(2,66)= 3.37, p= 0.04, FDR
p= 0.04). Follow-up, post hoc LSD tests showed that
higher KYNA was found in the high cytokine schizophrenia
subgroup relative to normal cytokine controls (p= 0.013),
whereas no other signiﬁcant subgroup differences were
detected (Fig. 4b).
Finally, a signiﬁcant difference was also found in
KYNA/QUINA ratio among cytokine subgroups (F(2,66)=
3.53, p= 0.04, FDR p= 0.04). Follow-up, post hoc LSD
tests showed that higher KYNA/QUINA ratio (Fig. 4c) was
found in the high cytokine schizophrenia subgroup relative
Fig. 3 Correlations of
kynurenine aminotransferases I
(a, b) and II (c, d) (KATI/II)
mRNA expression with glial
ﬁbrillary acidic protein (GFAP)
in postmortem brain tissue.
KATI mRNA expression
signiﬁcantly correlates with
GFAP mRNA in a controls (p=
0.001) and b schizophrenia (p=
0.008), whereas a signiﬁcant
correlation for KATII was only
found in d schizophrenia
patients (p= 0.03)
Fig. 4 Inﬂammatory subgroup differences of kynurenine (KYN)
pathway metabolites in postmortem brain tissue. a KYN/tryptophan
ratio was signiﬁcantly greater in people with schizophrenia who were
in the high cytokine subgroup (red, p < 0.001) compared to both low
cytokine controls (light blue) and low cytokine schizophrenia (pink)
subgroups. b Kynurenic acid (KYNA) was signiﬁcantly greater in
people with schizophrenia who were in the high cytokine subgroup
(red) compared to the low cytokine controls (light blue) (p= 0.013).
c KYNA/quinolinic acid ratio was signiﬁcantly greater in people with
schizophrenia who were in the high cytokine subgroup (red) as com-
pared to the normal cytokine control group (light blue, p= 0.01).
*p < 0.05, **p < 0.01, ***p < 0.001
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to normal cytokine controls (p= 0.01), whereas no other
signiﬁcant differences were detected.
Living cohort
Patient and control groups were not signiﬁcantly different
on the basis of sex ratios and both groups were in their early
to mid-30s on average in relation to age (Supplemental
Table S2c). As expected, the patients differed signiﬁcantly
from healthy controls on the basis of demographic, cogni-
tive, and brain volume variables (Supplemental Table S7),
but there were few signiﬁcant correlations between KYN/
TRP ratio and demographic variables in patients and con-
trols or with clinical variables in patients (Supplemental
Table S8), and no signiﬁcant differences in KP metabolites
on the basis of serotonin-altering medication (Supplemental
Table S9) or smoking status (Supplemental Table S10) in
patients. Attention was related to KYN/TRP ratio and
PANSS negative symptom severity in all patients (Supple-
mental Table S11), and there was a signiﬁcant differ-
ence between high and normal cytokine patient groups on
the basis of reading and attention (Supplemental
Table S12). There were some signiﬁcant, positive correla-
tions between cytokines and KYN/TRP ratio (Supplemental
Table S13).
Decreased plasma TRP and KYNA but increased
KYN/TRP ratio in schizophrenia
People with schizophrenia had signiﬁcantly lower levels of
plasma TRP (F(1,174)= 17.9, p < 0.001, FDR p= 0.003) and
plasma KYNA (F(1,175)= 20.1, p < 0.001, FDR p= 0.003)
but a signiﬁcantly higher KYN/TRP ratio (F(1,175)= 5.1,
p= 0.025, FDR p ≤ 0.05), relative to healthy controls
(Supplemental Figure S3). KYN/TRP ratio correlated sig-
niﬁcantly with CRP (r= 0.28, p= 0.01) and IL-1β mRNA
(r= 0.23, p= 0.03) in schizophrenia patients but not in
controls (CRP r= 0.13, p= 0.28; IL-1β mRNA, r=−0.14,
p= 0.26, Supplemental Table S13). There were no other
signiﬁcant correlations of the KYN/TRP ratio to other
cytokine mRNAs (IL-6, IL-8, IL-18, all ps > 0.05, Supple-
mental Table S13). There were no other signiﬁcant differ-
ences in plasma KP metabolite levels (KYN, F(1,174)= 2.7,
p= 0.07, FDR p= 0.1; 3-HK, F(1,175)= 1.4, p= 0.25, FDR
p= 0.28; QUINA, F(1,172)= 1.2, p= 0.28, FDR p= 0.28)
between patients and controls (see Supplemental
Figure S3).
Plasma KYN/TRP ratio is highest in a high cytokine
schizophrenia subgroup
We found signiﬁcant differences in KYN/TRP ratio among
diagnostic groups categorized on the basis of peripheral
cytokine levels (F3,143= 3.3, p= 0.02, FDR p= 0.02).
Follow-up LSD pairwise comparisons demonstrated sig-
niﬁcantly increased KYN/TRP ratio in the high cytokine
schizophrenia subgroup as compared to low cytokine con-
trols (p= 0.03), high cytokines controls (p= 0.004), and
the low cytokine schizophrenia subgroup (p= 0.03, see-
Fig. 5a). No other KP metabolites showed signiﬁcant
differences based on cytokine subgroups (all ts < 1.0, all
ps > 0.05).
Fig. 5 Elevated kynurenine (KYN)/tryptophan (TRP) ratio is related to
dorsolateral prefrontal cortex (DLPFC) volume and attention in
patients with schizophrenia (SCZ) who display elevated peripheral
cytokine levels. a Comparison of plasma KYN/TRP ratio in patients
with schizophrenia who display high cytokines levels to patients with
SCZ who display low cytokine levels and healthy controls with high
and low cytokine levels. Patients with SCZ who display elevated
proinﬂammatory cytokines (high) displayed signiﬁcantly elevated
KYN/TRP ratio compared to patients with schizophrenia who
displayed low cytokine levels (SCZ low) and healthy controls who
displayed low (Con low) and high (Con high) cytokine levels. *p <
0.05, **p < 0.01. b In SCZ patients with high proinﬂammatory cyto-
kines, a signiﬁcant negative correlation was detected between KYN/
TRP ratio and the attention domain, indicating worse attention per-
formance with elevated KYN/TRP ratio. c In SCZ patients with high
proinﬂammatory cytokines, a signiﬁcant negative correlation was
detected between KYN/TRP ratio and dorsolateral prefrontal cortex
(DLPFC) volume
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Attention performance and DLPFC volume
correlated inversely with plasma KYN/TRP ratio in
patients with schizophrenia who had high cytokine
levels
There were moderately strong, inverse, signiﬁcant correla-
tions of KYN/TRP ratio to attention (r=−0.45, p= 0.03,
n= 24) and rostral middle frontal gyrus volume (r=−0.44,
p= 0.04, n= 23) in the high cytokine subgroup of patients
with schizophrenia (see Fig. 5b, c). Thus, as KYN/TRP
ratio increased, attention and PFC volume decreased. No
signiﬁcant correlation was found between KYN/TRP ratio
and working memory (r= 0.12, p= 0.47). There were no
signiﬁcant correlations of brain (DLPFC) volumes or cog-
nition (working memory, attention) with the KYN/TRP
ratio in the low cytokine schizophrenia subgroup or low and
high cytokine healthy controls (all rs ≤ 0.30, all ps > 0.05).
Discussion
Our results support the involvement of the immune-
activated KP of TRP metabolism in the pathophysiology
of a subset of people with schizophrenia having elevated
cytokines from ﬁve distinct aspects: (1) elevation of KP
enzyme mRNAs in human brain, (2) alterations of
KP metabolites in human brain, (3) peripheral changes in
KP metabolites, (4) peripheral KP measures that link with
cognitive deﬁcits, and (5) peripheral KP measures that link
with structural human brain volumetric abnormalities. In
postmortem tissue, we showed that the mRNA for the
KYN-producing enzyme, TDO, and the KYNA-producing
enzymes, KATI/II, are increased in patients with schizo-
phrenia who also display elevated cytokine levels. Activa-
tion of the KAT arm of KP metabolism in the brain is likely
through astrocytes, since KAT is localized to astroglia and
KAT mRNAs positively correlated with the astroglial
marker, GFAP mRNA, in our sample, suggesting co-
regulation. Our observations are consistent with a model of
pathophysiology whereby a cytokine-induced intracerebral
overproduction of KYNA via KAT in astrocytes occurs in
at least some people with schizophrenia. Since KYNA
functions as an NMDA and alpha 7 receptor antagonist [9],
higher KYNA may provide a direct link to cortical changes
capable of yielding cognitive disruptions.
In accordance with our results on KP enzyme mRNA
showing increased KAT I and KAT II mRNA, we ﬁnd
signiﬁcant elevations of the KYN/TRP ratio and KYNA
levels in postmortem brain tissue of schizophrenia patients
with high proinﬂammatory cytokines. Thus the present
study conﬁrms a link between inﬂammation markers and
KP activation—to our knowledge for the ﬁrst time—within
the brains of patients with schizophrenia.
Consistent with the ﬁndings in postmortem brain tissue,
the KYN/TRP ratio was also increased in the plasma of
people with schizophrenia who had elevated cytokine levels
from the living cohort. The increased breakdown of TRP to
KYN points toward a cytokine-driven upregulation in the
KP in schizophrenia periphery and brain and is in line with
several previous studies [22, 30–32]. In support of the
hypothesis regarding inﬂammation in the brains of patients
with schizophrenia, we have previously demonstrated that
signiﬁcantly more patients with schizophrenia as compared
to controls have a high inﬂammatory biotype in independent
postmortem cohorts [2, 4] that has also been independently
replicated in peripheral blood from a living cohort [5, 42].
However, increases in circulating ratios of KYN/TRP may
or may not have a direct impact on the biochemistry and/or
function of the human brain. In support of an effect, we
report the ﬁrst evidence to link increased plasma KYN/TRP
ratio with reduced DLPFC volume and attention in people
with schizophrenia displaying increased proinﬂammatory
cytokines. Also, associations between a higher KYN/TRP
ratio and cognitive and structural abnormalities mimicking
NMDA-related deﬁcits would be consistent with increased
brain KYNA [30, 43]. Interestingly, reductions of brain
KYNA via a KATII inhibitor have produced improvements
of attention in rodents [44]. KYN and TRP both cross the
BBB and can therefore inﬂuence brain levels [35]. Espe-
cially in conditions of systemic inﬂammation, the majority
of brain KYN is derived from blood [9]. Moreover, our data
suggest that plasma levels of KYN/TRP can provide a
readily measureable peripheral indicator of the degree of
attention impairment and DLPFC brain volume loss in
people with schizophrenia who also display increased per-
ipheral cytokine levels. However, studies are needed mea-
suring KP enzyme activity and metabolites in plasma and
CSF of the same patients to further support these ﬁndings.
In contrast to the putative overproduction of KYNA in
the brain, our current ﬁnding supports other work [45–48]
showing reduced TRP and KYNA in circulation of people
with schizophrenia relative to controls. However, plasma
KYNA cannot cross the BBB and might therefore be
decoupled from brain KYNA in schizophrenia. While pre-
vious studies [45, 46, 49] have interpreted that the lower
blood levels of the proposed “neuroprotective” KYNA may
lead to schizophrenia-like changes due to putatively
increased “neurotoxic” QUINA, there is another possible
interpretation. We suggest that the lower KYNA levels in
circulation may reﬂect increased exit of TRP and KYN from
the blood and more entry into the brain, which could lead to
more substrate for brain KP activity and increased KYNA
production in the brains of people with schizophrenia. This
is consistent with a previous study showing that therapy
with the proinﬂammatory cytokine interferon-alpha in
patients with hepatitis C led to increases in KYN and
Kynurenine, cytokines, attention, and prefrontal cortex volume in schizophrenia
KYNA in CSF, simultaneous with the emergence of psy-
chiatric symptoms and also with concomitant decreases in
plasma TRP [50]. However, given that our brain and blood
measurements were not obtained from the same individuals,
our hypothesis pertaining to differences in the blood and
brain levels of TRP and KYNA within the same individuals
remains speculative.
Cytokines can activate microglia and astrocytes, which
are key players in KP metabolism. KAT I/II mRNA is
mainly produced in astrocytes [51] and we ﬁnd that KATI/II
mRNA was increased in the brains of people with schizo-
phrenia who were in the high cytokine subgroup, whereas
KMO mRNA was not statistically different according to
diagnosis or cytokine status. If the mRNA differences we
detected translate to changes in protein levels and enzyme
activity in the brain, then increased brain KYN may be
biased toward more production of KYNA and not neces-
sarily to more 3-HK or QUINA. Since astrocytes are con-
sidered a most important source of KYNA [28], we would
expect a relationship between the levels of KATI/II and the
astrocyte marker GFAP. Indeed, we previously found
increased GFAP mRNA and protein in those patients with
schizophrenia who also had elevated cytokines [52] and a
positive correlation between KATI/II mRNAs and both
GFAP and cytokine mRNAs in the present study. Further,
we found that there was a greater likelihood of more reac-
tive astrocyte morphology in the brains of patients with
schizophrenia who also had elevated cytokines compared to
controls, suggesting that astrocytes may contribute to the
elevations in KYNA we detect. However, anatomical
mapping the KATI/II mRNA and protein in the brains of
people with schizophrenia is necessary to support the cel-
lular source of increased KATI/II.
There are several limitations to this study. Our result of
increased KYN in the blood of people with schizophrenia
indicates that there may be a possible upregulation of the
ﬁrst step in the peripheral KP via conversion of TRP to
KYN. However, we have not directly measured peripheral
TDO protein levels or enzyme activity in our study. In fact,
the lack of direct activity-level measurements for any of the
KP enzymes within the blood and brain is a limitation of our
study, and further work is necessary to understand in more
detail which aspects of KP regulation are altered. Another
limitation is that we sampled from one point in time. Future
studies of living patients should address whether the dys-
regulation of KP metabolites remains stable over time or if
the metabolites vary throughout the course of the disease or
with acute exacerbations of symptoms. Longitudinal studies
will be important if we are to use KP metabolites and
immunological factors as clinical biomarkers [53], espe-
cially when cytokines are being considered as potential
biomarkers aimed at predicting conversion to illness in
high-risk samples [54]. A ﬁnal limitation for our study is
that since TRP levels can be inﬂuenced by multiple factors
(e.g., dietary and lifestyle) we can not rule out that these
between groups differences could be derived from potential
confounds that were not assessed in our study.
While the high inﬂammation biotype of schizophrenia is
a novel stratiﬁcation approach based on recent ﬁndings, as
described above, we have previously reported that a sig-
niﬁcantly higher percentage of patients with schizophrenia
had a high inﬂammatory biotype in three independent
cohorts [2, 4, 5, 42] and others have reported similar ﬁnd-
ings [55]. We did not explore differences in the high
cytokine control group in our postmortem sample due to the
small sample size in that subset; however, our living cohort
showed signiﬁcant differences on the KYN/TRP ratio in
high inﬂammation patients vs. each of the other inﬂam-
mation categories of patients and controls, including high
inﬂammation controls. Future studies should also investi-
gate high cytokine controls as assayed from brain tissue to
conﬁrm whether these changes are only found in schizo-
phrenia or are part of a more generalizable inﬂammatory
response. Further, in disease states there may be changes in
cell-subtype expression of mRNAs, particularly in schizo-
phrenia. The lack of cellular speciﬁcity for the postmortem
study is a limitation of the present study.
Also, although we did not show relationships between
antipsychotics and KP metabolites in the postmortem or
living samples, antipsychotics may be a limiting factor in
our study. In addition, although the two postmortem and
one living cohorts are all independent samples, we have
reported on each of these cohorts to some extent previously
in relation to other variables and hypotheses [2, 4, 5, 42].
There are also studies that did not conﬁrm an activation of
the brain immune system in schizophrenia [56]. Never-
theless, this report did initially ﬁnd an increase of IL-6
mRNA in schizophrenia compared to controls (p= 0.04,
FDR corrected), which was dismissed on the basis of further
post hoc statistical procedures (principal component-based
correction). We suggest caution should be applied to avoid
overcorrection of highly correlated tests in statistical
adjustment for cytokine differences between multiple
groups in future studies [57] and that a stratiﬁcation
approach may be more powerful in terms of deﬁning
neuroimmune-related pathophysiology in the brains of
people suffering from schizophrenia. One strength of our
present study is that we ﬁnd KP activation in high cytokine
schizophrenia patients in three independent cohorts (TRC,
SMRI, Living cohort).
In summary, this is the ﬁrst study showing alterations in
and associations among KP enzyme mRNAs, KP metabo-
lites in the brain and plasma, brain volume, and cognition in
subgroups of people with schizophrenia who have elevated
inﬂammation markers. Based on the results of the present
study and previous literature, we propose the following
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model for KP dysregulation in schizophrenia: inﬂammatory
mechanisms induce an increased conversion of TRP to
KYN in the periphery (which can cross the BBB) leading to
elevated brain KYN that is converted to KYNA by the
proinﬂammatory-driven increase in KAT enzyme activity
via increased mRNA in astroglia. This increased KYNA
eventually causes brain volume loss and attention impair-
ment via extensive NMDAR blockade. Future studies are
needed to conﬁrm this model and to test whether KP
metabolites and proinﬂammatory cytokines in either plasma
or CSF in psychosis risk and ﬁrst-episode psychosis are
useful clinical biomarkers for schizophrenia.
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